Testosterone-cipionate: Prolactinoma recurrence.

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 27-year-old transgender man (female at birth and transitioned to male) developed prolactinoma recurrence during treatment with testosterone-cypionate as female to male transgender hormonal therapy [route, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]